Are oncoantigens suitable targets for anti-tumour therapy?
about
Therapeutic antibodies: their mechanisms of action and the pathological findings they induce in toxicity studiesMicroenvironment, oncoantigens, and antitumor vaccination: lessons learned from BALB-neuT mice.Characterization of a genetic mouse model of lung cancer: a promise to identify Non-Small Cell Lung Cancer therapeutic targets and biomarkers.CSPG4: a prototype oncoantigen for translational immunotherapy studies.Classification of current anticancer immunotherapiesOncoantigens for an immune prevention of cancer.A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumorsThe Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward.Chimeric DNA Vaccines against ErbB2+ Carcinomas: From Mice to Humans.Injection site and regulatory T cells influence durable vaccine-induced tumor immunity to an over-expressed self tumor associated antigen.DNA vaccination against oncoantigens: A promise.Preclinical vaccines against mammary carcinoma.Maternal Immunization: New Perspectives on Its Application Against Non-Infectious Related Diseases in Newborns.2011: the immune hallmarks of cancer.Trial watch: Dendritic cell-based interventions for cancer therapy.A Virus-Like-Particle immunotherapy targeting Epitope-Specific anti-xCT expressed on cancer stem cell inhibits the progression of metastatic cancer in vivo.
P2860
Q26781698-285DC203-C4F7-4533-884D-9A63DFD3A6E2Q33786788-05D82094-1D26-4B16-8D5A-A163ECF9C55EQ33851540-68ECCC13-640D-431D-9B68-B8D76AB5FB0EQ33862585-7913CA60-C01A-4B58-8DC7-BB21EE23EA66Q35149637-C93CFAB5-5E9C-4829-BBC6-BA4B930584ACQ35232253-23194424-F314-4E7E-97D1-613C09C1E44FQ35918770-3F0CA79A-B96F-451F-85CB-FC4C2AE2C099Q36509433-FC3FFF5A-187E-4664-B210-9435100B6AB5Q37137404-E4FC3AD4-C236-4771-840A-ED287D3B4ED4Q37195269-E2FD06A3-C08D-4FE5-8AB5-17DF01514F36Q38022032-97719B67-E50A-4010-91C1-FCA9D949EB4BQ38160252-757984B3-E211-483F-9A01-FFCCD84465DCQ38649517-70C1666C-1292-44BF-9AF5-E815314CD6E0Q42217850-FD4A33E9-9A4E-4D3A-A9F8-741AC4310D50Q42867339-E710D196-37A7-4BEC-8210-FD8985755FE0Q55264209-BA77C247-7523-4644-970D-CE0B5D2C6736
P2860
Are oncoantigens suitable targets for anti-tumour therapy?
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Are oncoantigens suitable targets for anti-tumour therapy?
@ast
Are oncoantigens suitable targets for anti-tumour therapy?
@en
Are oncoantigens suitable targets for anti-tumour therapy?
@nl
type
label
Are oncoantigens suitable targets for anti-tumour therapy?
@ast
Are oncoantigens suitable targets for anti-tumour therapy?
@en
Are oncoantigens suitable targets for anti-tumour therapy?
@nl
prefLabel
Are oncoantigens suitable targets for anti-tumour therapy?
@ast
Are oncoantigens suitable targets for anti-tumour therapy?
@en
Are oncoantigens suitable targets for anti-tumour therapy?
@nl
P2860
P356
P1476
Are oncoantigens suitable targets for anti-tumour therapy?
@en
P2093
Guido Forni
P2860
P2888
P304
P356
10.1038/NRC2208
P407
P577
2007-09-01T00:00:00Z
P6179
1036100878